#5152 Introduction:
 Ensuring pathologically tumor free surgical margins reduces local recurrence rates following breast conserving surgery for breast cancer or DCIS. There is no general agreement regarding the definition of a clear margin but units with an agreed policy report reduced local recurrence rates. In our unit all patients with a surgical clearance of <5mm are offered further surgery either by mastectomy or by re-excision. We have examined factors that may predict residual disease in re-excised tissues.
 Method:
 All attempted breast conserving operations between 01/01/2004 to 31/09/2007 were identified from a dedicated database. Patient age, presentation (symptomatic or screening), surgeon (any of 4 surgeons), weight of tissue removed, tumour size, grade, presence of lymphovascular invasion (LVI) and the closest radial margin (categorised as involved, <2mm, 2-5mm) were examined.
 Results:
 Breast conservation was attempted in 605 women (mean age 60; 297 symptomatic, 308 screening). Further surgery was performed in 166 (27.4%) women, including 89 (14.7%) mastectomies. Median tumour size was 20mm (range 0-109). Residual disease was found in 83(50%) of re excisions (66/111 with involved margins, 16/40 for non involved margins up to 2mm, and 1/15 for margins over 2mm). On univariate analysis excision margin (OR=0.33, p=0.000) and total tumor size (OR=4.0 p=0.045 for the smallest size quartile versus the largest) were associated with residual disease. On multivariate analysis only tumor margin remained predictive (OR for <2mm vs involved: 0.46, p=0.043; OR for 2-5mm vs involved: 0.05, p=0.004).
 Conclusion:
 In a unit with an aggressive re-excision policy, involved or close surgical margins predict the presence of residual disease in re-excision specimens. A margin of greater than 2mm reduces the risk of residual disease to 1/20 of that seen with microscopically involved margins. This study supports a 2mm minimum radial margin policy when attempting breast conservation for breast malignancy. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5152.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.